A recent treatment combination for chronic lymphocytic leukemia (CLL) has received approval, offering a potentially less disruptive option for patients facing this blood cancer. The U.S. Food and Drug Administration (FDA) has approved a fixed-duration therapy of acalabrutinib, marketed as Calquence by AstraZeneca, in combination with venetoclax, for adults with previously untreated CLL or small lymphocytic lymphoma (SLL). This approval marks a significant step forward, providing an all-oral regimen that demonstrated superior progression-free survival and a manageable safety profile compared to traditional chemoimmunotherapy in the pivotal AMPLIFY Phase III trial. The announcement came on December 8, 2024.
CLL is a type of cancer that affects the blood and bone marrow, characterized by the slow accumulation of abnormal lymphocytes. While treatment options have expanded in recent years, many still involve intravenous chemotherapy, which can be burdensome for patients. The approval of acalabrutinib plus venetoclax offers a convenient, all-oral alternative, potentially improving quality of life during treatment. The combination therapy is particularly notable for its fixed duration, meaning patients receive treatment for a defined period, rather than continuing until disease progression. This approach is increasingly favored in CLL management, offering the potential for treatment-free remission and reduced long-term toxicity.
Superior Progression-Free Survival in the AMPLIFY Trial
The approval is based on the results of the Phase III AMPLIFY trial, which compared Calquence plus venetoclax to standard chemoimmunotherapy in 523 previously untreated patients with CLL. The trial demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) with the combination therapy. Specifically, patients receiving acalabrutinib and venetoclax experienced a 35% reduction in the risk of disease progression or death compared to those receiving chemoimmunotherapy (hazard ratio [HR] 0.65; 95% confidence interval [CI] 0.49-0.87; p=0.0038) at a median follow-up of 41 months. Remarkably, 77% of patients treated with the combination remained progression-free at three years.
When combined with obinutuzumab, the reduction in risk of disease progression or death was even more pronounced, reaching 58% compared to standard-of-care chemoimmunotherapy (HR 0.42; 95% CI 0.30-0.59; p<0.0001). Median PFS was not reached for either experimental arm, while the chemoimmunotherapy arm had a median PFS of 47.6 months. Interim overall survival (OS) data also showed a favorable trend for the Calquence plus venetoclax arm (HR 0.33; 95% CI 0.18-0.56; p<0.0001), although the data were considered immature at the time of analysis and will continue to be assessed.
Understanding the Medications
Acalabrutinib (Calquence) is a second-generation Bruton’s tyrosine kinase (BTK) inhibitor. BTK is a protein that plays a crucial role in the survival and growth of CLL cells. By inhibiting BTK, acalabrutinib helps to block the signaling pathways that drive cancer progression. Venetoclax is a BCL-2 inhibitor, targeting another protein essential for CLL cell survival. BCL-2 prevents cancer cells from undergoing programmed cell death (apoptosis). By inhibiting BCL-2, venetoclax promotes apoptosis in CLL cells. Combining these two targeted therapies creates a synergistic effect, maximizing their anti-cancer activity.
Safety and Side Effects
The safety profile of acalabrutinib plus venetoclax was generally manageable in the AMPLIFY trial. While side effects occurred, they were often less severe than those associated with traditional chemotherapy. Common adverse events included neutropenia (low white blood cell count), diarrhea, and upper respiratory tract infections. Serious adverse events were reported, but were generally manageable with supportive care. The New England Journal of Medicine published the full results of the study, detailing the safety and efficacy data.
What So for Patients
This approval provides a new, effective treatment option for individuals newly diagnosed with CLL or SLL. The all-oral nature of the regimen, coupled with the demonstrated improvement in progression-free survival, offers a compelling alternative to traditional chemotherapy. Patients considering this treatment should discuss the potential benefits and risks with their healthcare provider to determine if it is the right choice for them. The availability of a fixed-duration therapy also offers a psychological benefit for many patients, knowing that treatment will have a defined endpoint.
Researchers are continuing to investigate the long-term effects of acalabrutinib and venetoclax, including overall survival and the potential for durable remissions. Further studies are also exploring the use of this combination in other subtypes of B-cell malignancies. The ongoing assessment of overall survival is a key secondary endpoint of the AMPLIFY trial, and results are eagerly anticipated.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
The FDA’s approval of acalabrutinib plus venetoclax represents a significant advancement in the treatment of CLL, offering a more convenient and effective option for patients. The next step will be continued monitoring of long-term outcomes and further research to optimize the use of this promising combination therapy. Share your thoughts on this new treatment option in the comments below, and please share this article with anyone who may identify it helpful.
